Swiss MedTech Startup Rhovica Raises €2.5 Million

The round was led by M2care, with support from Kickfund, Valuemaker, and several business angels.

Martin Hlavica, CEO and Co-founder of Rhovica, stated: “This fundraising marks an important milestone for Rhovica. The trust of our investors strengthens our ability to advance the development of SoNav and move closer to making this solution available to patients in need.”

Founded in 2023 by neurosurgeons Martin Hlavica and Thomas Rhomberg, Rhovica Neuroimaging is developing solutions to improve emergency care for patients with life-threatening elevated brain pressure.

Read Also - Danish Startup Propane Secures €1 Million In Pre-Seed Round

A common intervention in such cases is the placement of an extraventricular drainage (EVD) catheter. Currently, this procedure is either done freehand at the bedside—fast but imprecise—or delayed in the operating room using navigation systems. This compromise between speed and accuracy can negatively impact outcomes.

Rhovica’s SoNav system tackles this issue by offering real-time visual guidance for catheter insertion directly at the bedside through integrated sensors. It also enables continuous monitoring of brain ventricles, potentially reducing the need for repeated CT scans, enhancing patient safety, and lowering healthcare costs.

Florence Thueux, President of M2care, commented: “M2care combines investment capacity with hands-on expertise to de-risk early HealthTech ventures to Series A readiness. Rhovica reflects this approach addressing a clear clinical need with a strong team and a technology that can transform emergency neurosurgery. We are proud to actively support the company in this next phase of development.”

Rhovica tackles a critical challenge in emergency neurosurgery: the fast and safe placement of life-saving EVD catheters to relieve increased intracranial pressure caused by severe trauma or bleeding.

Positioned in the growing neurosurgical device market—projected to expand between 4.5% and 14.2%—Rhovica is set for significant growth.

To accelerate development, Rhovica has appointed Carsten Laue, Managing Director at M2care, to its Board of Directors. His medtech strategy and company-building expertise will help advance SoNav™ toward clinical adoption.

Laue added: “By joining Rhovica’s board, I look forward to actively supporting the team in translating a strong clinical need into a viable MedTech solution. The project’s origin in emergency neurosurgical care, combined with the founders’ complementary expertise, reflects precisely the type of innovation that M2care is set up to accelerate.”

About Rhovica

Founded in 2023, Rhovica Neuroimaging is revolutionizing care for patients with head injuries and raised intracranial pressure. Led by two neurosurgeon co-founders and an expert team, their SoNav system enhances emergency treatment, saving time and lives, improving outcomes, and reducing hospital costs.